TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
1-Year Est. Return
18.15%
1 Year Est. Return
+18.15%
AUM
$2.56B
AUM Growth
-$71.2M
(-2.7%)
Holding
186
Top Buys
| 1 | +$20.3M | |
| 2 | +$13.5M | |
| 3 | +$13.2M | |
| 4 |
Insulet
PODD
|
+$12.6M |
| 5 |
Tenet Healthcare
THC
|
+$12.1M |
Top Sells
| 1 | +$35.4M | |
| 2 | +$24.2M | |
| 3 | +$21.6M | |
| 4 |
Bristol-Myers Squibb
BMY
|
+$13.1M |
| 5 |
UnitedHealth
UNH
|
+$13.1M |
Sector Composition
| 1 | Healthcare | 96.11% |
| 2 | Real Estate | 2.09% |
| 3 | Industrials | 0.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
BPMC
176
DELISTED
Blueprint Medicines
BPMC
| – | – |
-67,710
|
|
||
177
Kura Oncology
KURA
$972M
| – | – |
-283,281
|
|
||
178
Labcorp
LH
$22B
| – | – |
-46,609
|
|
||
179
Lantheus
LNTH
$3.95B
| – | – |
-79,495
|
|
||
180
Mersana Therapeutics
MRSN
$138M
| – | – |
-6,495
|
|
||
181
Merus
MRUS
$7.28B
| – | – |
-69,025
|
|
||
182
Option Care Health
OPCH
$4.95B
| – | – |
-64,975
|
|
||
183
Ultragenyx Pharmaceutical
RARE
$3.26B
| – | – |
-67,065
|
|
||
184
Syndax Pharmaceuticals
SNDX
$1.63B
| – | – |
-117,717
|
|
||
185
Travere Therapeutics
TVTX
$3.11B
| – | – |
-418,520
|
|